• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Aquestive Therapeutics Inc.

    4/24/26 5:05:43 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AQST alert in real time by email
    DEFA14A 1 ny20064249x2_defa14a.htm DEFA14A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934 (Amendment No.    )

    Filed by the Registrant ☒
    Filed by a Party other than the Registrant  ☐
    Check the appropriate box:
     ☐
    ​
    ​
    Preliminary Proxy Statement
     ☐
    ​
    ​
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐
    ​
    ​
    Definitive Proxy Statement
    ☒
    ​
    ​
    Definitive Additional Materials
     ☐
    ​
    ​
    Soliciting Material under §240.14a-12

    AQUESTIVE THERAPEUTICS, INC.
    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):
    ☒
    ​
    ​
    No fee required
     ☐
    ​
    ​
    Fee paid previously with preliminary materials
     ☐
    ​
    ​
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     


     Your Vote Counts!  *Please check the meeting materials for any special requirements for meeting attendance.  Smartphone users  Point your camera here and vote without entering a control number  For complete information and to vote, visit www.ProxyVote.com  Control #  V92180-P48218  AQUESTIVE THERAPEUTICS, INC. 30 TECHNOLOGY DRIVE  WARREN, NJ 07059  AQUESTIVE THERAPEUTICS, INC.  2026 Annual Meeting  Vote by June 9, 2026  11:59 PM ET  You invested in AQUESTIVE THERAPEUTICS, INC. and it’s time to vote!  You have the right to vote on proposals being presented at the 2026 Annual Meeting of Stockholders. This is an important notice  regarding the availability of proxy materials for the stockholder meeting to be held on June 10, 2026 at 9:30 AM Eastern Time.  Get informed before you vote  View the 2026 Proxy Statement and 2025 Annual Report on Form 10-K online OR you can receive a free paper or email copy of the  material(s) by requesting prior to May 27, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.  Vote Virtually at the Meeting*  June 10, 2026  9:30 AM, Eastern Time  Virtually at: www.virtualshareholdermeeting.com/AQST2026 
     

     Vote at www.ProxyVote.com  THIS IS NOT A VOTABLE BALLOT  This is an overview of the proposals being presented at the upcoming stockholder meeting. You are encouraged to access and review the complete proxy materials. Please follow the instructions on the reverse side to access the proxy materials and to vote these important matters.  Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.  1. To elect Gregory B. Brown, M.D., John S. Cochran and Abigail L. Jenkins as Class II members of the Board of Directors, each to serve for a three-year term until the Company’s 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified.  For All  Nominees:  Gregory B. Brown, M.D.  John S. Cochran  Abigail L. Jenkins  2. To approve, on a non-binding advisory basis, the compensation of our named executive officers.  For  3. To ratify the appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026.  For  4. To act upon any other matters that may properly come before the 2026 Annual Meeting or any adjournment or postponement thereof.  Voting Items  Board Recommends  V92181-P48218 
     



    Get the next $AQST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AQST

    DatePrice TargetRatingAnalyst
    4/24/2026$8.00Outperform
    Oppenheimer
    6/2/2025$7.00Outperform
    Oppenheimer
    12/17/2024$17.00Overweight
    Cantor Fitzgerald
    5/10/2024$8.00Outperform
    Leerink Partners
    4/11/2024$10.00Overweight
    Piper Sandler
    3/28/2024$7.00Outperform
    Raymond James
    More analyst ratings

    $AQST
    SEC Filings

    View All

    SEC Form 10-Q filed by Aquestive Therapeutics Inc.

    10-Q - Aquestive Therapeutics, Inc. (0001398733) (Filer)

    5/13/26 4:08:39 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)

    5/13/26 4:04:40 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Aquestive Therapeutics Inc.

    DEFA14A - Aquestive Therapeutics, Inc. (0001398733) (Filer)

    4/24/26 5:05:43 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Zalewski Thomas A. was granted 100,000 shares (SEC Form 4)

    4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)

    5/19/26 12:02:01 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Barber Daniel sold $35,413 worth of shares (8,257 units at $4.29), decreasing direct ownership by 1% to 660,574 units (SEC Form 4)

    4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)

    5/18/26 2:03:23 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Regulatory Affairs Cioffi Melina covered exercise/tax liability with 1,667 shares, decreasing direct ownership by 0.61% to 273,200 units (SEC Form 4) (withholding obligation)

    4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)

    5/18/26 12:36:51 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LIBERVANT issued to AQUESTIVE THERAPEUTICS INC

    Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    4/29/24 7:48:13 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

    Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union, and the United KingdomCompleted AQST-108 phase 1 study in subjects with androgenic alopecia with no safety issues observedEntered into a $150 million debt facility with Oaktree Capital Management, L.P.Company to host investor call on May 14, 2026, at 8:00am ET WARREN, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovativ

    5/13/26 4:01:00 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

    WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the refinancing of its existing debt facility with a new $150 million debt facility with funds managed by Oaktree Capital Management, L.P. ("Oaktree"). This transaction provides additional flexibility to fund the launch of Anaphylm™, if approved by the FDA.   At closing, Oaktree provided $55.0 million, which was primarily used to repay the Company's existing loan in the aggregate principal amount of $45 mi

    5/12/26 9:31:25 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET

    WARREN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the first quarter ended March 31, 2026 and provide an update on recent developments in its business after market close on Wednesday, May 13, 2026. Management will host a conference call for investors at 8:00 a.m. ET on Thursday, May14, 2026. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of t

    5/6/26 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on Aquestive Therapeutics with a new price target

    Oppenheimer resumed coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $8.00

    4/24/26 8:31:20 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer resumed coverage on Aquestive Therapeutics with a new price target

    Oppenheimer resumed coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $7.00

    6/2/25 8:47:02 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Aquestive Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Aquestive Therapeutics with a rating of Overweight and set a new price target of $17.00

    12/17/24 7:27:23 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Financials

    Live finance-specific insights

    View All

    Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

    Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union, and the United KingdomCompleted AQST-108 phase 1 study in subjects with androgenic alopecia with no safety issues observedEntered into a $150 million debt facility with Oaktree Capital Management, L.P.Company to host investor call on May 14, 2026, at 8:00am ET WARREN, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovativ

    5/13/26 4:01:00 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET

    WARREN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the first quarter ended March 31, 2026 and provide an update on recent developments in its business after market close on Wednesday, May 13, 2026. Management will host a conference call for investors at 8:00 a.m. ET on Thursday, May14, 2026. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of t

    5/6/26 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 daysOn track to submit regulatory applications for Anaphylm in Canada and the EU in 2026Extends revenue sharing agreement with RTW to June 30, 2027Excluding one-time items, meets 2025 guidance for revenue and non-GAAP adjusted EBITDA lossGuides to end FY2026 with cash and cash equivalents of $70 millionCompany to host investment community conference call on March 5, 2026 WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring m

    3/4/26 4:01:00 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Leadership Updates

    Live Leadership Updates

    View All

    Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer

    Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective April 2, 2026Lori J. Braender to remain in a non-executive role as Corporate Secretary after nearly eight years as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary WARREN, N.J., March 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective Apr

    3/20/26 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer

    Board-certified allergist and leading food allergy and anaphylaxis researcher joins Aquestive to support Anaphylm™ (dibutepinephrine) sublingual film NDA resubmission and pipeline WARREN, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Matthew Greenhawt, MD, MBA, MSc, as Chief Medical Officer, strengthening its leadership team as the Company prepares to resubmit its Anaphylm™ New Drug Application (NDA) to the United Stated Food and Drug Admi

    2/18/26 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024

    WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced its expected addition to the broad-market Russell 3000® and Russell 2000® Indexes at the conclusion of the 2024 Russell U.S. indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24, 2024. "We are honored that Aquestive is joining the Russell 3000 Index, which represents the 3,000 largest U.S. public

    6/18/24 8:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aquestive Therapeutics Inc.

    SC 13G/A - Aquestive Therapeutics, Inc. (0001398733) (Subject)

    11/14/24 3:47:19 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aquestive Therapeutics Inc.

    SC 13G - Aquestive Therapeutics, Inc. (0001398733) (Subject)

    4/1/24 6:21:14 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aquestive Therapeutics Inc.

    SC 13G - Aquestive Therapeutics, Inc. (0001398733) (Subject)

    2/14/24 3:24:42 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care